 Furthermore, DDI risk increases dramatically with age, with patients age 70-79 having a 50-fold risk increase in comparison to patients aged 0-19 . Interestingly, several null models demonstrate that this risk increase is not due to increased polypharmacy with age.
<meaning-changed>  Furthermore, DDI risk increases dramatically with age, with patients age 70-79 having a 50-fold risk increase in comparison to patients aged 0-19 . Interestingly, several null models demonstrate that this risk increase is not due to increased polypharmacy with age.
 Furthermore, DDI risk increases dramatically with age, with patients age 70-79 having a 50-fold risk increase in comparison to patients aged 0-19 . Interestingly, a null model demonstrates that age and women-specific risks from increased polypharmacy far exceed expectations in those populations. This suggests that social and biological factors are at play.